| 赵立群,李雅莉,徐灵彬,张 洁,张娟妮.布地奈德福莫特罗治疗支气管哮喘患者的临床疗效及对患者血清炎性因子水平的影响[J].现代生物医学进展英文版,2017,17(24):4723-4726. |
| 布地奈德福莫特罗治疗支气管哮喘患者的临床疗效及对患者血清炎性因子水平的影响 |
| Clinical Efficacy of Budesonide and Formoterol Fumarate Powder in the Treatment of Patients with Bronchial Asthma and Its Effect on the Serum Levels of Inflammatory Factors |
| Received:January 05, 2017 Revised:January 31, 2017 |
| DOI：10.13241/j.cnki.pmb.2017.24.030 |
| 中文关键词: 慢性支气管哮喘 布地奈德福莫特罗 肺功能 IL-33 MMP-9 SGRQ评分 |
| 英文关键词: Chronic bronchial asthma Budesonide and Formoterol Fumarate Powder Pulmonary function IL-33 MMP-9 SGRQ score |
| 基金项目: |
|
| Hits: 337 |
| Download times: 193 |
| 中文摘要: |
| 摘要 目的：探讨布地奈德福莫特罗吸入治疗对慢性支气管哮喘患者的临床疗效及其对患者血清炎性因子水平、肺功能和生活质量的影响。方法：选择2014年2月至2016年2月于我院呼吸内科就诊并确诊为慢性支气管哮喘患者123例，根据随机数字表法分为观察组65例和对照组58例。比较两组患者治疗前后血清白介素17(IL-17)、白介素33(IL-33)、基质金属蛋白酶9(MMP-9)、肺功能、生活质量评分的变化、临床疗效有效率及不良反应的发生情况。结果：观察组的总有效率为92.3%(60/65)，显著高于对照组(81.03%，P＜0.05)。治疗后，两组患者的血清IL-17、IL-33水平与治疗前相比均显著降低(P＜0.05)，且观察组显著低于对照组(P＜0.05)；两组血清MMP-9水平与治疗前相比差异均无统计学意义(P＞0.05)；观察组患者的第一秒用力呼吸容积(FEV1)、峰值呼气流速(PEF)与第一秒用力呼气容积与用力肺活量比值(FEV1/FVC)水平均明显增加，且观察组上述指标明显高于对照组(P＜0.05)；圣．乔治呼吸问卷(SGRQ)评分结果显示观察组患者的生活质量显著高于对照组患者。结论：布地奈德福莫特罗吸入治疗对慢性支气管哮喘临床效果显著，可显著控制炎症反应，改善肺功能，显著提升患者生活质量。 |
| 英文摘要: |
| ABSTRACT Objective: To explore the clinical efficacy of Budesonide and Formoterol Fumarate Powder in the treatment of patients with bronchial asthma and its effect on the serum levels of inflammatory factors. Methods: 123 cases treated and diagnosed as bronchial asthma in our hospital from February, 2014 to February, 2016 were randomly divided into the observation group (65 cases) and control group (58 cases). The serum levels of IL-17, IL-33, MMP-9, pulmonaryfunction,quality of life, total effective rate and incidence of adverse reactions were compared between the two groups. Results: The total effective rate of observation group was 92.3%, which was significantly higher than that of the control group (81.03%, P＜0.05). After therapy, the serum level of IL-17, IL-33 in both groups were largely decreased compared with those before therapy (p＜0.05), and those of observation group were significantly lower than the control group (p＜0.05); the serum level of MMP-9 in both groups showed no statistical difference compared with that of before therapy. Similarly, the level of FEV1, PEF and FEV1/FVC of observation group were obviously increased compared with those before therapy (p＜0.05) and were significantly higher than those of the control group (p＜0.05); the quality of life in the observation group was better than that of the control group based on the SGRQ score (p＜0.05). Conclusion: Budesonide and Formoterol Fumarate Powder was effective on the patients with chronic bronchial asthma, which could control the inflammatory reactions, improve the pulmonary function as well as the quality of life. |
|
View Full Text
View/Add Comment Download reader |
| Close |
